Home » AGEB Journal » Issues » Volume 70" » Fasc.2 - Symposium » Article details

Treatment of cirrhotic ascites

Journal Volume 70 - 2007
Issue Fasc.2 - Symposium
Author(s) J. Schouten, P.P. Michielsen
Full article
Full Article
VIEW FREE PDF
Division of Gastroenterology and Hepatology, University Hospital Antwerp, Belgium.

Cirrhosis is the most common cause of ascites and accounts for almost 85% of all cases. It is the most common complication of cir- rhosis, after development of ascites only 50% of patients will sur- vive for 2 to 5 years. Successful treatment is dependent on accurate diagnosis of the cause of ascites. Because sodium and water retention is the basic abnormality leading to ascites formation, restriction of sodium intake and enhancing sodium excretion is the mainstay of the treatment of ascites. Patients with cirrhosis and ascites must limit sodium intake to 2 gram per day. Enhancement of sodium excretion can be accomplished by usage of oral diuretics. The recommended initial dose is spironolactone 100-200 mg/d and furosemide 20-40 mg/d. usual maximum doses are 400 mg/d of spironolactone and 160 mg/d of furosemide. The recommended weight loss in patients without peripheral edema is 300 to 500 g/d. There is no limit to the daily weight loss of patients who have edema. About 90% of patients respond well to medical therapy for ascites. Refractory ascites is defined as fluid overload that is unre- sponsive to sodium restricted diet and high dose diuretic treatment (diuretic resistant) or when there is an inability to reach maximal dose of diuretics because of adverse effects (diuretic-intractable). It has a poor prognosis. Treatment options for patients with refractory ascites are serial therapeutic paracentesis, transjugular intrahepatic stent-shunt (TIPS) or peritoneovenous shunt and liver transplantation. TIPS should be considered in patients who repeatedly fail large-volume paracentesis and have relatively pre- served liver functions. Liver transplantation is the only modality that is associated with improved survival. (Acta gastroenterol. belg., 2006, 69, 217-222).

© Acta Gastro-Enterologica Belgica.
PMID 17715638